Canada
Review Article
Bone-Seeking Targeted Radio-Nuclide Therapy BT-RNT) in Management of Metastatic Castration-Resistant Prostate Cancer (mCRPC): Shifting from
Palliation to Improving Survival
Author(s): Vimoj J Nair, Colin Malone, Patricia Moretto, Eugene Leung and Shawn MaloneVimoj J Nair, Colin Malone, Patricia Moretto, Eugene Leung and Shawn Malone
Background: The purpose of this article is to review the role of bone-seeking targeted radionuclide therapy (BT-RNT) in metastatic prostate cancer. The mechanisms of actions, radiobiology and clinical benefits of BT-RNTs will be reviewed.
Methods: Relevant studies of CRPC and targeted therapies were identified from literature and clinical trial databases, websites, and conference abstracts.
Results: BT-RNT in mCRPC has a proven beneficial palliative role in treatment of patients with mCRPC. The use of these agents as a monotherapy as well as combination with other palliative therapies are evolving. Among the various BT-RNT’s the alpha emitter 223Ra which is highly targeted and well tolerated has shown significant clinical benefit and survival advantage in this patient population.
Conclu.. Read More»
DOI:
10.4172/2155-9619.1000202
Nuclear Medicine & Radiation Therapy received 706 citations as per Google Scholar report